Security Snapshot

Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE) Institutional Ownership

CUSIP: 578784100

13F Institutional Holders and Ownership History from Q1 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

116

Shares (Excl. Options)

49.61MFull value: 49,607,216 · shares · 30 Sep 2026

Price

$27.18

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+191,497
Value change
+$1,739,323
Number of holders
116
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
55,581,463
SEC-reported price per share
$31.93
Insider filing price
$31.93
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • MAZE - Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share is tracked under CUSIP 578784100.
  • 116 institutions reported positions in Q3 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 160 to 116 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.75BFull value: $1,745,780,907 · USD · 30 Jun 2026
    to
    $1.35BFull value: $1,348,683,596 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 116 institutions filings for Q3 2026.

Open SEC evidence

Security key

578784100

13F reference period

Q3 2026

13F holders

116

13D/G owners

9

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
MAZE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Frazier Life Sciences Public Fund, L.P. 9% +16% $174,515,671 +$39,762,017 4,342,266 +30% Frazier Life Sciences Public Fund, L.P. 31 Dec 2025
ARCH Venture Fund X, L.P. 9.4% $36,215,266 4,120,053 ARCH Venture Fund X, L.P. 31 Mar 2025
Deep Track Capital, LP 9% +30% $59,431,096 +$13,927,661 3,948,910 +31% Deep Track Capital, LP 30 Jun 2025
Third Rock Ventures IV, L.P. 6.7% -29% $101,217,178 -$20,385,000 3,723,958 -17% Third Rock Ventures IV, L.P. 30 Sep 2026
BlackRock, Inc. 5.4% $88,865,731 2,978,114 BlackRock, Inc. 30 Jun 2026
JANUS HENDERSON GROUP PLC 5.8% -21% $78,390,380 -$9,531,082 2,858,876 -11% JANUS HENDERSON GROUP PLC 31 Mar 2026
Matrix Capital Management Company, LP 3.5% -37% $42,880,026 -$21,586,725 1,653,684 -33% Matrix Capital Management Company, LP 30 Sep 2025
GV 2019, L.P. 2.9% -52% $57,528,994 -$42,419,680 1,388,583 -42% Alphabet Holdings LLC 31 Dec 2025
Foresite Capital Fund IV, L.P. 1.4% -70% $15,790,022 -$47,922,789 608,948 -75% James Tananbaum 30 Sep 2025
As of 30 Sep 2026, 116 institutional investors reported holding
49.61MFull value: 49,607,216 · shares · 30 Sep 2026
shares of Maze Therapeutics, Inc. - Common Stock, $0.001 par value per share (MAZE). This represents 89% of the company’s total
55.58MFull value: 55,581,463 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
76%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Frazier Life Sciences Management, L.P. 9.5% 5,282,915 3.6% $143,589,630
ARCH Venture Management, LLC 7.4% 4,120,053 6.9% $111,983,041
Deep Track Capital, LP 7.3% 4,083,969 1.9% $111,002,277
TRV GP IV, LLC 6.7% 3,723,958 68% $101,217,178
Janus Henderson Group Ltd. 6.1% 3,408,045 0.04% $92,715,864
T. Rowe Price Investment Management, Inc. 4.4% 2,429,811 0.05% $66,043,000
VANGUARD CAPITAL MANAGEMENT LLC 3.4% 1,879,317 0% $51,079,836
a16z Capital Management, L.L.C. 3.1% 1,702,225 0.23% $46,266,476
Venrock Adviser, LLC 2.8% 1,545,616 2% $42,009,843
Alphabet Inc. 2.5% 1,388,583 0.04% $37,741,686
MARSHALL WACE, LLP 2.1% 1,166,108 0.03% $31,694,815
BRAIDWELL LP 2.1% 1,149,735 1.3% $31,249,797
STATE STREET CORP 2% 1,122,155 0% $30,500,173
FARALLON CAPITAL MANAGEMENT, L.L.C. 2% 1,107,814 0.16% $30,110,385
GEODE CAPITAL MANAGEMENT, LLC 1.7% 955,071 0% $25,964,545
TRV GP V, LLC 1.7% 950,800 5.4% $25,842,744
Driehaus Capital Management LLC 1.7% 947,544 0.18% $25,754,246
Logos Global Management LP 1.7% 935,000 1.5% $25,413,300
GOLDMAN SACHS GROUP INC 1.5% 846,632 0% $23,011,458
Casdin Capital, LLC 1.5% 843,857 1% $22,936,033
ArrowMark Colorado Holdings LLC 1.4% 767,383 0.99% $20,857,470
Woodline Partners LP 1.3% 747,050 0.06% $20,304,819
Aberdeen Group plc 0.87% 485,273 0.02% $13,189,720
SPHERA FUNDS MANAGEMENT LTD. 0.66% 366,288 1.5% $9,955,708
VANGUARD PORTFOLIO MANAGEMENT LLC 0.57% 316,985 0% $8,615,652

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
7
Headline period
Q3 2026
Rows shown
1-7 of 7
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 49,607,216 $1,348,683,596 +$1,739,323 $27.18 116
2026 Q2 58,534,404 $1,745,780,907 +$185,206,340 $29.84 160
2026 Q1 51,677,471 $1,543,189,088 +$68,960,987 $29.85 164
2025 Q4 48,370,369 $2,003,833,642 +$199,439,391 $41.43 144
2025 Q3 42,970,633 $1,114,223,528 +$108,250,260 $25.93 93
2025 Q2 38,836,437 $476,719,891 -$14,337,293 $12.27 74
2025 Q1 40,038,674 $441,393,439 +$441,263,796 $11.01 68
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .